Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Jagsonpal Pharmaceuticals is targeting about 10% overall growth for the medium-term, including the current year. Jagsonpal Pharmaceuticals targets about 10% overall revenue growth for the current fiscal year, with expectations of accelerated growth thereafter (Page 12).
From Jagsonpal Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Jagsonpal Pharmaceuticals is targeting about 10% overall growth for the medium-term, including the current year.
- There is an expectation of accelerated growth beyond the current year, with more detailed guidance to be provided in the coming weeks.
- New product launches are planned but not publicly disclosed yet; these will contribute to future growth.
- Growth has moderated recently due to strategic underperformance of a key product, Dydrogesterone, which dropped from Rs.40 crore to Rs.10 crore in 24 months.
- The company will focus on launching products in more difficult categories requiring concept selling, aiming for slower but sustainable growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No specific current or future capex or strategic investment details were disclosed in the call.
- The management highlighted cautious new product launches, focusing on less crowded, difficult categories requiring concept selling for sustainable buildup rather than quick scale.
- There is openness to inorganic growth via acquisitions, with funding capacity through cash reserves (~Rs.150 crores), quarterly cash flow (approx. Rs.15 crores), leveraging the balance sheet, and shareholder backing.
- They prefer acquisitions within a moderate size, smaller than large peers like Torrent, but are confident to take bigger acquisition steps due to improved organizational capability.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹64 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jagsonpal Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key concall takeaways from Morepen Laboratories Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key concall takeaways from Anuh Pharma Ltd's Q2 FY26 earnings call — and how it…
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key concall takeaways from Themis Medicare Ltd's Q2 FY26 earnings call…
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q2 FY26 results?
Jagsonpal Pharmaceuticals is targeting about 10% overall growth for the medium-term, including the current year. Jagsonpal Pharmaceuticals targets about 10% overall revenue growth for the current fiscal year, with expectations of accelerated growth thereafter (Page 12).
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
No specific current or future capex or strategic investment details were disclosed in the call. - The management highlighted cautious new product launches, focusing on less crowded, difficult categories requiring concept selling for sustainable buildup rather than quick scale. - There is openness to inorganic growth via acquisitions, with funding capacity through cash reserves (~Rs.150 crores), quarterly cash flow (approx.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.